Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.

@article{Saridaki2010MechanismsOR,
  title={Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.},
  author={Zacharenia Saridaki and Vassilis Georgoulias and John Souglakos},
  journal={World journal of gastroenterology},
  year={2010},
  volume={16 10},
  pages={1177-87}
}
Metastatic colorectal cancer (mCRC) continues to be counted as a major health problem. The introduction of newer cytotoxics, irinotecan and oxaliplatin, has achieved a significant improvement in survival rates. Novel targeted therapies (bevacizumab, and cetuximab) in combination with most efficient chemotherapy regimens have pushed the median survival beyond the 2-year mark and increased the proportion of patients which could benefit from resection of metastatic lesions. In addition, several… CONTINUE READING
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…